Last reviewed · How we verify
Relma-cel
Relma-cel is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.
Relma-cel is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. Used for Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
At a glance
| Generic name | Relma-cel |
|---|---|
| Also known as | CD19-targeted Chimeric Antigen Receptor(CAR) T Cells, JWCAR029, if necessary can add other anti-SLE treatment such as corticosteroids, immunosuppressants, biologics |
| Sponsor | Shanghai Ming Ju Biotechnology Co., Ltd. |
| Drug class | CAR-T cell therapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Relma-cel involves engineering a patient's own T lymphocytes to express a chimeric antigen receptor (CAR) targeting a tumor-associated antigen, enabling the modified cells to recognize, proliferate, and destroy malignant cells. The CAR-T cells are expanded ex vivo and reinfused into the patient where they persist and provide durable anti-tumor immunity. This approach leverages the patient's immune system for targeted cancer cell elimination.
Approved indications
- Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Hematologic toxicity
- Infection
Key clinical trials
- Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma (PHASE2)
- Glofitamab Combined With CAR-T Therapy in R/R DLBCL (PHASE2)
- CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors (PHASE2)
- Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma (NA)
- Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies (PHASE2)
- Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma (PHASE2)
- Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (PHASE2)
- Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |